Mobile screening for major depressive disorder in adults from an ethnically and socioeconomically diverse population.

Mobile screening for major depressive disorder in adults from an ethnically and socioeconomically diverse population. - MOOD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON56488

Enrollment

1786

Registered

2023-04-11

Start date

2024-09-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression downheartedness

Interventions

This research will make use of a personally designed app (YourResearch 2021) solicit for digital informed consent as well as socio-demographic information. Furthermore, both Euro Quality of Life-5D

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: At least 18 years old Have a smartphone

Exclusion criteria

Exclusion criteria: Has been previously diagnosed with MDD or related disorder in the past 5 years or is still taking related medicine.s.

Design outcomes

Primary

Measure	Time frame
Primary outcomes of the trial include participants* quality of life after 24 months compared to the quality of life at the start of the study as measured by the EQ-5D. Although only 3 out of 5 items on this questionnaire relate to mental problems and social functioning, evidence suggests that it is highly sensitive to MDD. Because the fifth question of the EQ-5D has the strongest relation with mental health, we will report outcomes on that question separately as well.	—

Measure

Time frame

Primary outcomes of the trial include participants* quality of life after 24 months compared to the quality of life at the start of the study as measured by the EQ-5D. Although only 3 out of 5 items on this questionnaire relate to mental problems and social functioning, evidence suggests that it is highly sensitive to MDD. Because the fifth question of the EQ-5D has the strongest relation with mental health, we will report outcomes on that question separately as well.

—

Secondary

Measure	Time frame
We will also examine the occurrence and severity of symptoms as measured by the PHQ, and participant adherence using Kaplan-Meier curves for the proportion of patients completing 0%, >50%, and 100% of tests, patients* experience of screening. It will also provide invaluable information regarding the duration and severity of MDD symptoms across participants in second and third screening arm, which will be the subject of further study under Aim 2.	—

Measure

Time frame

We will also examine the occurrence and severity of symptoms as measured by the PHQ, and participant adherence using Kaplan-Meier curves for the proportion of patients completing 0%, >50%, and 100% of tests, patients* experience of screening. It will also provide invaluable information regarding the duration and severity of MDD symptoms across participants in second and third screening arm, which will be the subject of further study under Aim 2.

—

Countries

Netherlands

Contacts

Public ContactI. (Inge) M.C.M. Kok

Erasmus MC, Universitair Medisch Centrum Rotterdam

i.dekok@erasmusmc.nl010-7038460

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)